A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Sarcoma,Soft Tissue
Interventions
DRUG

INT230-6

INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.

DRUG

Eribulin

Eribulin IV

DRUG

Trabectedin

Trabectedin infusion

DRUG

Pazopanib

Pazopanib pill

Trial Locations (17)

15526

Helios Klinikum Bad Saarow, Bad Saarow

19106

University of Pennsylvania - Abramson Cancer Center, Philadelphia

19111

Temple University - Fox Chase Cancer Center, Philadelphia

27710

Duke Cancer Center, Durham

28050

Centro Integral Oncologico Clara Campal (HM CIOCC), Madrid

43210

The James Cancer Hospital and Solove Research Institute, Columbus

48333

Profound Research LLC, Farmington Hills

68114

Nebraska Methodist Hospital, Omaha

69008

Centre Leon Berard, Lyon

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

90403

Sarcoma Oncology Center, Santa Monica

90404

University of California Los Angeles (UCLA) - Santa Monica Cancer Care, Santa Monica

06519

Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location, New Haven

M5G 2M9

Princess Margaret Cancer Centre, Toronto

04103

Universitäres Krebszentrum (UCCL), Leipzig

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08740

Hospital Universitari Vall Hebron, Barcelona

Sponsors
All Listed Sponsors
collaborator

Premier Research

OTHER

lead

Intensity Therapeutics, Inc.

INDUSTRY